Apstemtx

1 known investors

APstem is developing a regenerative cell therapy built on a patented adult stem cell platform (Guide-Integrated Adult Stem Cells / APSCs) derived from immunoregulatory "guide cells" fused with mesenchymal stromal cells from healthy donors. Its allogeneic, off-the-shelf therapies target autoimmune and degenerative conditions such as Type 1 Diabetes, IBD, and multiple sclerosis.

BiotechLongevityMedical Devices